November 11, 2019 - Non-regulatory SynAct receives approval from the Swedish Medical Product Agency and the Swedish Ethical Review Authority regarding the clinical Phase IIa study with AP1189
October 21, 2019 - Regulatory SynAct conducts private placement and fully guaranteed rights issue with the aim of increasing the commercial value of AP1189
March 29, 2019 - Regulatory SynAct applies for start of phase IIa clinical study in patients with active arthritis
February 25, 2019 - Non-regulatory John Haurum and Terje Kalland are proposed as new members of the Board of Directors in SynAct Pharma AB
February 11, 2019 - Regulatory SynAct reported positive phase I results for candidate drug AP1189 and prepared funding for broadened phase II programmes
